Methylglyoxal in Correlation with Persistent Pulmonary Hypertension of Neonates | ||||
| The Egyptian Journal of Hospital Medicine | ||||
| Article 140, Volume 89, Issue 2, October 2022, Page 7031-7036 PDF (571.95 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ejhm.2022.272504 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Eman R. Youness; Mones M. Abu Shady; Hisham W. Bader; Mohamed EL-Sonbaty; Shaimaa A Hashem; WalaaAlsharany Abuelhamd; Hanan Hanna 
| ||||
| Abstract | ||||
| Background: Methylglyoxal has been documented to increase in circulation and at tissue level not only in diabetes but also in hypertension. Objective: Our objective was to report the association between methylglyoxal (MG) levels in the blood and newborn persistent pulmonary hypertension. Subjects and Methodology: Forty near-term and term neonates with evidence of persistent pulmonary hypertension (PPHN); were further alienated into two groups, Group (1):20 cases with PPHN with hypoxia and Group (2):20 cases with PPHN without hypoxia,40 healthy cross-matched controls with normal hearts were included in the study. Echocardiography was done to establish the diagnosis of PPHN, APGAR score, and methylglyoxal (MG) levels, random blood sugar,complete blood picture, serum creatinine, blood urea and oxygenation index were measured. Results: A highly significant increase in the mean levels of MG was found in cases (whether with or without hypoxia) compared to controls (31.15± 19, 18.6 ± 10.01 ng/uL versus 12.8 ± 6.2respectively). Conclusion: Methylglyoxal initiates pulmonary hypertension either by suppressing the production of nitric oxide (vasodilator) or by releasing vasoconstrictors. Furthermore, there was strong evidence that systolic blood pressure, hemoglobin, blood sugar, and pulmonary hypertension were the main predictors of MG | ||||
| Keywords | ||||
| Methylglyoxal; Pulmonary hypertension; Neonates; Hypoxia | ||||
|
Statistics Article View: 116 PDF Download: 207 |
||||
